Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:IMCR NASDAQ:SOPH NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$29.14+1.0%$25.89$16.10▼$32.14$1.36B1.51491,326 shs57,784 shsIMCRImmunocore$29.98-2.1%$30.87$27.44▼$40.71$1.53B0.74427,890 shs27,415 shsSOPHSOPHiA GENETICS$5.53+2.3%$4.84$2.59▼$5.70$377.38M1.01164,397 shs88,771 shsWVEWAVE Life Sciences$7.18-0.9%$9.65$5.02▼$21.73$1.38B-1.324.28 million shs575,075 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-2.60%-7.20%+14.53%+31.98%+45.97%IMCRImmunocore-0.36%+9.71%-4.19%-4.46%+2.34%SOPHSOPHiA GENETICS+7.57%+3.45%+10.20%+12.50%+80.00%WVEWAVE Life Sciences-0.69%+2.55%+1.97%-46.17%+11.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$29.14+1.0%$25.89$16.10▼$32.14$1.36B1.51491,326 shs57,784 shsIMCRImmunocore$29.98-2.1%$30.87$27.44▼$40.71$1.53B0.74427,890 shs27,415 shsSOPHSOPHiA GENETICS$5.53+2.3%$4.84$2.59▼$5.70$377.38M1.01164,397 shs88,771 shsWVEWAVE Life Sciences$7.18-0.9%$9.65$5.02▼$21.73$1.38B-1.324.28 million shs575,075 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-2.60%-7.20%+14.53%+31.98%+45.97%IMCRImmunocore-0.36%+9.71%-4.19%-4.46%+2.34%SOPHSOPHiA GENETICS+7.57%+3.45%+10.20%+12.50%+80.00%WVEWAVE Life Sciences-0.69%+2.55%+1.97%-46.17%+11.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 2.92Moderate Buy$43.0047.56% UpsideIMCRImmunocore 2.30Hold$57.7592.65% UpsideSOPHSOPHiA GENETICS 2.33Hold$7.5035.75% UpsideWVEWAVE Life Sciences 2.87Moderate Buy$27.50283.28% UpsideCurrent Analyst Ratings BreakdownLatest SOPH, IMCR, WVE, and AVBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.005/4/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.004/27/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/24/2026AVBPArriVent BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$33.00 ➝ $45.004/21/2026IMCRImmunocore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SOPHSOPHiA GENETICS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AVBPArriVent BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.44 per shareN/AIMCRImmunocore$400.02M3.80N/AN/A$7.52 per share3.99SOPHSOPHiA GENETICS$77.27M4.90N/AN/A$0.67 per share8.25WVEWAVE Life Sciences$71.80M19.23N/AN/A$2.66 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$166.31M-$4.41N/AN/AN/AN/A-62.49%-58.11%5/11/2026 (Estimated)IMCRImmunocore-$35.51M-$0.70N/AN/AN/A-6.68%-7.09%-2.54%N/ASOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%N/AWVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%N/ALatest SOPH, IMCR, WVE, and AVBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88N/AN/AN/AN/AN/A5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.01 million$106.68 million5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million3/5/2026Q4 2025AVBPArriVent BioPharma-$0.87-$0.78+$0.09-$0.78N/AN/A3/3/2026Q4 2025SOPHSOPHiA GENETICS-$0.20-$0.28-$0.08-$0.28$21.20 million$21.71 million2/26/2026Q4 2025WVEWAVE Life Sciences-$0.28-$0.30-$0.02-$0.30$15.68 million$17.25 million2/25/2026Q4 2025IMCRImmunocore-$0.28-$0.60-$0.32-$0.60$145.48 million$104.48 million2/14/2026Q4 2025IMCRImmunocoreN/A-$0.60N/A-$0.60N/A$104.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A12.8312.83IMCRImmunocore1.034.044.01SOPHSOPHiA GENETICS1.052.061.84WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%IMCRImmunocore84.50%SOPHSOPHiA GENETICS31.59%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma18.58%IMCRImmunocore10.40%SOPHSOPHiA GENETICS4.88%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4046.37 million37.75 millionN/AIMCRImmunocore32050.69 million45.42 millionOptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableWVEWAVE Life Sciences240192.38 million146.25 millionOptionableSOPH, IMCR, WVE, and AVBP HeadlinesRecent News About These CompaniesWave Life Sciences: Good Platform, Mixed Clinical Trial Data, HoldMay 7 at 11:02 AM | seekingalpha.comHC Wainwright Has Bullish Forecast for WVE Q2 EarningsMay 4, 2026 | americanbankingnews.comHC Wainwright Expects Higher Earnings for WAVE Life SciencesMay 4, 2026 | marketbeat.comCanaccord Genuity Reaffirms Their Buy Rating on Wave Life Sciences (WVE)May 3, 2026 | theglobeandmail.comA Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price DeclineMay 3, 2026 | finance.yahoo.comPictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVEMay 2, 2026 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for WAVE Life Sciences (NASDAQ:WVE) Stock PriceMay 2, 2026 | americanbankingnews.comWAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street ZenMay 2, 2026 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 2, 2026 | americanbankingnews.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Given New $43.00 Price Target at Canaccord Genuity GroupApril 30, 2026 | marketbeat.comWAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...April 29, 2026 | finance.yahoo.comWAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What HappenedApril 29, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPSApril 29, 2026 | marketbeat.comWAVE Life Sciences Q1 Earnings Call HighlightsApril 28, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 5.5% Higher - Time to Buy?April 28, 2026 | marketbeat.comWave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue EstimatesApril 28, 2026 | zacks.comWave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 28, 2026 | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Should You Sell?April 24, 2026 | marketbeat.comWAVE Life Sciences (WVE) Projected to Post Earnings on TuesdayApril 24, 2026 | marketbeat.comWave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From AnalystsApril 23, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSOPH, IMCR, WVE, and AVBP Company DescriptionsArriVent BioPharma NASDAQ:AVBP$29.14 +0.29 (+1.01%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Immunocore NASDAQ:IMCR$29.98 -0.64 (-2.10%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.SOPHiA GENETICS NASDAQ:SOPH$5.52 +0.13 (+2.31%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.WAVE Life Sciences NASDAQ:WVE$7.18 -0.07 (-0.90%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
